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INSIGHTS INTO MOUSE MODELS OF HUMAN DOWN SYNDROME 
MAYESO CHITHAMBO 
ABSTRACT 
 Down syndrome, also referred to as trisomy 21, is a chromosomal 
abnormality in which the 21st human chromosome is partially or entirely 
duplicated.  It is associated with a myriad of characteristics, including distinct 
facial deformities, intellectual disability, a heart defect, low muscle tone, and 
development of Alzheimer’s disease symptoms with aging.  This duplication is 
associated with increased levels of gene expression relative to what is present in 
euploid cells and disrupts the structure of some gene products.  This study 
examines current mouse models of trisomy 21, describes a bioinformatics 
approach to evaluate relationships between genes on chromosome 21, and to 
determine the role they may play in Down syndrome associated intellectual 
disability.   
The Ts1Rhr, Tc1, and Ts65Dn mouse models are compared and 
contrasted to human trisomy 21. Representation of intellectual disability is 
determined by how the mice in each model perform on learning and memory 
tasks. Each model is examined for duplication of Down syndrome associated 
genes as well as for body weight, cerebral size, cerebellar size, balance, motor 
coordination, learning and memory, attention, activity, presence or absence of a 
heart defect, and presence or absence of a craniofacial defect.  
 v 
Next, a bioinformatics approach is proposed as tool with the capacity to 
examine the individual genes on chromosome 21, the relationships between the 
genes, group genes together by functional similarity and biological implication, 
and then establish which of these groups are enriched. The combined evaluation 
of mouse models and bioinformatics can be used as an innovative way to study 
the involvement in the intellectual disability associated with Down syndrome. 
Through the review of current mouse models and the evaluation of individual 
chromosome 21 genes using bioinformatics resources, the study seeks to 
determine what insights on intellectually disability can be gained.  
 vi 
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INTRODUCTION 
Down syndrome, caused by trisomy of the 21st chromosome, is the most 
common live born chromosomal abnormality causing a wide spectrum of 
physical, cognitive, and medical complications. Down syndrome is characterized 
by decreased attention, decreased executive function, delayed language 
acquisition, reduced working memory, a lower than average IQ, and seizure 
activity (in 5-13% of children) (Antonarakis et al., 2004; Head et al., 2013; Lott, 
2012; Megarbane, et al., 2009).  Down Syndrome sufferers are also more likely 
than healthy individuals to suffer from sleep apnea, visual and auditory deficits, 
thyroid dysfunction, and have a ten fold increased risk for autism spectrum 
disorders than non-Down syndrome individuals (Esbensen, 2010).  First 
manifesting in infancy, hypotonia, or decreased resistance to passive muscle 
stretch, causes the ligaments to be too lax which delays overall motor 
development (Antonarakis et al., 2004; Head, et al., 2013).  This joint laxity 
reduces stability of gait and increases the energy cost needed for physical action, 
leading to a host of musculoskeletal abnormalities such as decreased bone 
mass, decreased ability to control posture, predisposition to fractures, higher 
than average body mass index, lower than average lean mass, and reduced 
cardiovascular strength.  
Blood testing and ultrasound are often used for prenatal screening for 
Down syndrome.  During the first trimester, the mother receives blood testing to 
evaluate various protein and hormone levels.  The outcome of the blood test is 
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used to ascertain if a patient’s fetus is at risk for Down syndrome (Ehrich, et al., 
2011).  Next an ultrasound is used to look for the presence of fluid behind the 
fetus’s neck, which is often an indicator of Down syndrome (ACOG, 2011). 
If the fetus is determined to be at increased risk for developing Down 
syndrome, diagnostic testing is used to collect a sample of genetic material to 
look for the presence of an extra copy of chromosome 21.  The diagnostic testing 
sample can be collected using amniocentesis, chorionic villus, or percutaneous 
umbilical blood sampling.  An amniocentesis is typically performed during the 
second trimester. It involves inserting a needle into the mother’s abdomen, 
penetrating the uterine wall to access the amniotic sac for amniotic fluid 
extraction.  Chorionic villus sampling is a procedure that collects a sample of the 
placenta transcervically or transabdominally by using ultrasound to help guide 
the healthcare provider to the correct location.  This procedure is typically 
performed during the first trimester.  Lastly, percutaneous umbilical sampling 
entails taking fetal blood sample from the umbilical cord.  This diagnostic 
procedure is the most accurate, but cannot be performed until later in the 
pregnancy.  Prediagnostic testing does pose a small risk of miscarriage and 
other difficulties, but these complications are fairly rare (Chemistry, Second 
trimester: Cordocentesis (percutaneous umbilical blood cord sampling, PUBS), 
2012).  These diagnostic tests are typically only performed if indicated by a 
screening test, if the mother is older than 35, or if there is a family history of 
genetic diseases (Chemistry, First Trimester: Chorionic Villus Sampling, 2012). 
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Despite the availability of prenatal screening and diagnostic tests, most 
Down syndrome patients are diagnosed as infants.  Health care providers are 
trained to recognize the classic physical traits associated with the condition. 
Down syndrome infants and children are most recognizable by their noticeably 
upward slanting eyes, small nose bridges, flat facial profiles, enlarged tongues, 
small upper lips, small ears and cognitive delays (Figure 1). Because of the 
notable impact Down syndrome has on everyday functioning, investigating how 
Down syndrome characteristics develop is of great interest to the scientific 
community (Megarbane, et al., 2009) (Lott, 2012). 
 
Figure 1. Outline of common indicators of Down syndrome. (National Institute on 
Alcohol Abuse and Alcoholism) 
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 During childhood, multisystem health problems become more apparent.  
Down syndrome children are more likely to have vision, hearing, respiratory, and 
thyroid problems than normal children.  They also often must have surgery to 
treat the congenital heart defect associated with T21.  An increasing number of 
young children with Down syndrome are being encouraged to take advantage of 
mainstream education and daycare with unaffected children.  Though they often 
need special education or hired caretakers to help them manage their education, 
this is not always the case. 
 By the time they reach adulthood, individuals with Down syndrome have 
usually received specialized education on self-care, at home care, and related 
topics so that they can function as independently as possible.  Several advocacy 
groups, such as the National Down Syndrome Society, have been instrumental in 
creating more support for adults living with DS (National Down Syndrome 
Society, 2012).  These adults have access to several housing options, such as 
assisting living communities and group homes.  More and more adults are 
participating in secondary and post-secondary education, entering romantic 
relationships, and becoming employed (National Health Service, 2013) (National 
Down Syndrome Society, 2012).  
 The average life expectancy for individual with Down syndrome is at an all 
time high of 43-55 years of age (Head, et al.,  2013).  By age 40, most sufferers 
are undergoing the neuropathological changes associated with Alzheimer’s 
disease.  This includes the presence of senile plaques and neurofibrillary tangles 
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that are caused by the overexpression of APP.  By age 50, most of these 
individuals can be expected to show noticeable signs of cognitive decline and/or 
dementia (Head, et. al, 2013). 
 
What is Trisomy 21? 
Trisomy 21 results from a single duplication when either partial or the full-length 
segment of the long arm of chromosome 21 is present in three copies instead of 
two, as shown in Figure 2.  Three underlying processes can result in 
chromosome 21 duplication: nondisjunction, translocation, or mosaicism of 
chromosome 21 (Antonarakis et al., 2004).  Down syndrome anomalies that 
result from trisomy 21 are primarily of maternal origin, and become more likely in 
incidence with increasing maternal age (Dierssen et al., 2009).   
 
Figure 2. Trisomy 21 Karotype. (National Human Genome Research Institute, 
2008)The figure above depicts a karyotype of human trisomy 21.  As described in 
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the paragraph above, the 21st chromosome is present in three copies instead of 
two, leading to Down Syndrome. 
 
Nondisjunction is the most common cause of trisomy 21, accounting for 
about 90% of cases (Patterson, 2009). It occurs when two chromosome 21 
containing cells do not separate properly during meiosis, as is necessary for 
normal cell division.  The insufficient chromosomal separation associated with 
nondisjunction produces duplications or deletions of entire chromosomes.  This 
can result in two types of abnormal products: cells with three copies of the 
chromosome and cells with one copy. Cells with a single copy (shown on the 
bottom right) of chromosome 21 do not survive. Cells with three copies do 
survive, resulting in three copies of the chromosome in all cells (Antonarakis et 
al., 2004).   
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Figure 3. Diagram of Nondisjunction. (Genetic Diseases, 2014). 
In nondisjunction, sister chromatids or homologous pairs fail to separate properly.  
The outcome is either a cell with an extra copy of a chromosome, or lacking a 
copy. 
In translocation, either part of or the entire chromosome relocates to a 
new place as shown in Figure 4.  This can occur either on the same chromosome 
or a different one.  In trisomy 21 associated translocation, this duplication 
attaches to another chromosome, instead of remaining as a separate entity.  
Translocation can be inherited from a phenotypically normal parent who has 46 
total chromosomes in per cell, each present in two copies  (Antonarakis et al., 
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2004).  Translocation is responsible for about 4% of Down syndrome cases 
(Antonarakis et al., 2004). 
 
Figure 4. Diagram of Chromosomal translocation (Chromosomal 
Translocations, 2012). During translocation, chromosomes rearrange such that a 
portion of one chromosome attaches to another. 
 
Mosaicism is a phenomenon in which an individual has cells that vary in 
genetic makeup.  As shown in Figure 5, cells start out normally, but at some point 
a particular cell is made with 47 chromosomes instead of 46.  The 47 
chromosome-containing cell is subsequently used as a template to create other 
cells, producing numerous aneuploid cells with the same error; there are cells, 
however that have the correct number of chromosomes (Papavassilio et al., 
2009; Antonarakis et al., 2004) Antonarakis, Lyle, Dermitzakis, Thus, the 
organism will have a mixture of cells, some with 46 chromosomes and others 
with 47.  Mosaicism can occur in one progenitor or across progenitors, and can 
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be detected through blood testing if there is mosaicism of the blood cell line.  
Mosaicism accounts for about 2% of all cases of Down syndrome (Antonarakis et 
al., 2004). Very few studies have compared simple trisomy to mosaic trisomy, 
although the severity of mosaic Down syndrome tends to reflect the proportion of 
aneuploidy cells relative to euploid cells (Papavassiliou et al., 2009).   
  
Figure 5. Diagram of Mosaicism (O'Connor, 2011). In mosaicism, an 
individual has some cell lines with an extra copy of chromosome 21, and some 
that have the appropriate number of copies. 
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Historical Evidence for the Existence of DS 
Examinations of 2500-year-old South American artifacts provided the earliest 
evidence of individuals with Trisomy 21 traits.  The characteristic facial features 
of Down syndrome have also been described in 500 Alzheimer’s patients of 
Toltecan Mexico. Their remains are consistent with the current understanding of 
the progression Alzheimer’s disease development in Down syndrome patients.  
In light of this evidence, as well as supplementary portrayals in 15th and 16th 
century art, Down syndrome has likely been present for ages (Megarbane et al., 
2009).  Esquirol first described the phenotype in the late 1830’s, whose main 
focus was distinguishing the features of mental retardation from the features of 
psychosis (Megarbane, et al., 2009).  Down syndrome first appeared in the 
modern literature in 1886 when John Langdon Down who recognized that the 
characteristic facial appearance and associated cognitive impairment was 
common among individuals who were unrelated, and thus had no reason to 
share the same appearance (Megarbane, et al., 2009).  Based on the notion that 
these individuals resembled natives of Mongolia, who (at the time) were 
inaccurately associated with underdevelopment, the afflicted were referred to as 
“Mongoloids.” From then on mongolism became a synonymous Down syndrome 
(Megarbane et al., 2009).  
The cause of Down syndrome was unknown for quite some time. In the 
early 1930s, Waardenburg speculated that the phenotype was caused by a gene 
dosage imbalance, which disturbs the environment in which different genes 
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develop and alters the way in which they are ultimately expressed (Megarbane et 
al., 2009).  Waardenburg and Davenport first suggested that chromosomal 
abnormality might be an underlying potential cause but, it was not until the 
creation of karyotyping techniques in the late fifties that Lejeune and Jacobs 
were each able to independently link this set of abnormalities to the presence of 
an extra copy of chromosome 21 (Megarbane et al., 2009).  It was later 
confirmed that the disease could also be caused by translocation and partial 
trisomy of the chromosome.  In the 1960s, geneticists decided the term 
“mongolism” implied an unfounded racial bias, and therefore decided to rename 
the disease “Down syndrome,” which refers to complete trisomy, partial trisomy, 
or translocations (Megarbane et al., 2009). 
The link between gene dosage and the Down syndrome phenotype was 
explored in early attempts at medical treatment; vitamin supplements were 
believed to equalize the impact of the increased gene dosage (Megarbane et al., 
2009).  Though experimental studies were not performed to support this notion, 
different vitamin and mineral concoctions were used to treat Down syndrome 
children in the 1960s (Megarbane et al., 2009).  
The abnormalities associated with trisomy 21 are thought to be associated 
gene-dosage imbalances, or increased gene expression levels relative to what is 
present in euploid cells.  Altering the expression of critical genes causes changes 
in protein expression patterns. This can have deleterious consequences, such as 
disturbing the stoichiometry of multimeric subunits and disrupting the complex 
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structure causing receptor complexes to develop with irregular function and 
structure (Lott, 2012).  Trisomy 21 is associated with decreased synaptic 
acetylcholine esterase and decreased responsiveness of acetylcholine release 
mechanisms (Toiber et al., 2010).  On the other hand, when proteins are 
expressed at higher quantities than normal, transporter molecules are become 
saturated more quickly (Antonarakis et al., 2004).  The specificity of 
concentrations of both morphogens and regulatory elements, which are affected 
by increased gene expression, is critical to development and gene expression 
(Antonarakis et al., 2004). In the most common form of DS, amyloid precursor 
protein (APP) is overexpressed, which results in Alzheimer’s neuropathology by 
age 40.  When the brain of a Down syndrome individual processes beta amyloid, 
there is an increase in amyloid secretion and generation of free radicals.  The 
subsequent increase in oxidative stress leads to immune dysfunction.  Trisomy 
21 is associated with deposition of beta amyloid in the frontal cortex that 
transitions to deeper cortical areas earlier in life than normal (Head et al., 2013; 
Lott, 2012). These beta amyloid deposits cause a combination of behavioral 
deficits that are consistent with the progression of Alzheimer’s disease (Lott, 
2012).  Disturbances related to gene expression imbalances are thought to incite 
the developmental instability of hormone receptors, transporter molecules, 
morphogens, regulatory elements, and neurotransmitter concentrations. 
In the late 1980s and early 1990s, Down syndrome research shifted to 
focus on determining whether duplication of a specific region of chromosome 21 
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is enough to result in the characteristic features.  Since there are distinct 
phenotypic resemblances amongst unrelated individuals, it seemed likely that a 
genetic change was present (Korenberg et al., 1990). Therefore, finding a way to 
model a population of subjects with trisomy 21 can enhance our understanding of 
how the trisomy 21 genotype develops into the phenotype. The Down Syndrome 
Critical Region (or DSCR) is the band 21q22, 21q11.1-21q22.2 was originally 
identified as an area thought to contain loci when present as a third copy of the 
phenotype.  The concept was established based on observations of patients with 
partial triplications of regions of chromosome 21; phenotypes of these individuals 
were used to define regions associated with particular traits (Korenberg et al., 
1990). This region was linked with the characteristic facial appearance, 
congenital heart defect, and mental retardation of Down syndrome patients.  
However, triplication of the DSCR was not enough to cause the hippocampal 
dysfunction or craniofacial abnormalities of the disease (Olson et al., 2007).  In 
light of this evidence, the scientific opinion has shifted to the view that DSCR is a 
region that corresponds with increased susceptibility to Down syndrome 
(Antonarakis et al., 2004).   
In theory, trisomy of genes in the susceptibility region would lead to the 
distinct Down syndrome phenotype, but only if specific interactions with other 
trisomic and nontrisomic genes were also present (Dierssen et al., 2009).  Since 
it is known that modification of gene expression caused by trisomy leads to the 
Down syndrome phenotype, the next logical steps were to try to identify specific 
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genes whose expression was affected by duplication and thus contribute to the 
Down syndrome phenotype.   
The concept of imprinted genes is becoming more heavily researched in 
conditions whose traits are the direct result of gene dosage. In humans, 
autosomal gene expression usually results from two alleles such that genes are 
equally expressed from the maternal and paternal alleles (Ishida & Moore, 2013).  
When genes are inherited this way, two working copies are present.  In a few 
genes, genomic imprinting occurs causing either the paternal allele or the 
maternal allele of a particular gene to be expressed (Oakey & Beechey, 2002).  
The current thinking is that the expressed gene may contain a biological marker 
in order to retain expression. Imprinted genes could also being associated with 
intellectual disability.  Genomic imprinting has predominantly been observed is 
genes that influence fetal development, while evidence of genomic imprinting in 
the brain has also been supported (Gregg et al., 2010).  These genes are 
especially vulnerable targets for pathology because only a single genomic 
change is necessary to modify their function.  In the diploid state, organisms are 
presumably less impacted by the negative effects of dysfunction of any one allele 
in a gene pair. Since the proportion of gene dosage surrounding intellectual 
disability is difficult to narrow down, it is conceivable that imprinted genes play a 
role. Future research on the presence of imprinted genes on chromosome 21 
could uncover the root cause of intellectual disability if it occurs by this 
mechanism.   
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Genes implicated in DS 
There are a number of genes that have been linked to specific Down 
syndrome traits. Dual-specificity tyrosine-phosphorylation regulated kinase 1A, or 
DYRK1A, is located in the area initially identified as the DSCR and an extra copy 
of it is present in Down syndrome individuals (Antonarakis et al., 2004).  
DYRK1A is a proline directed serine/threonine kinase that depends on 
autophosphorylation of its tyrosine for activation of the catalytic domain; it is 
involved in various pathways, including transcription, translation, and signal 
transduction (Toiber et al., 2010). In neurons, DYRK1A is localized to the nucleus 
and cytoplasm.  Overexpression of this kinase in mice is associated with 
hyperactivity, impaired neuromotor development, impaired spatial learning and 
memory, which are all features also observed in Down syndrome (Park et 
al.,2008).  Excess DYRK1A contributes to these abnormalities by altering the 
brain’s splicing machinery, which decreases cell proliferation and cell 
differentiation (Park et al., 2008).  Moreover, DYRK1A appears to be closely 
associated with neurodegenerative diseases such as Alzheimer’s disease, 
Parkinson’s disease, and Huntington’s disease.  DYRKA1 plays a role in beta 
amyloid production and senile plaque formation and is found in the neurofibrillary 
tangles or Down syndrome and Alzheimer’s brains (Park et al., 2008).   
RCAN1, regulator of calcineurin, inhibits the phosphatase activity of 
calcineurin A.  Located at 21q22.12, RCAN1 consists of seven exons and forms 
a negative feedback loop in a Ca2+ signaling pathway (Park et al.,2008).  In 
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addition to its role in late long-term potentiation and memory, RCAN is involved in 
the regulation of neuronal oxidative stress and the neurotransmission process at 
synapses. While the precise mechanism by which RCAN1 contributes to the 
Down syndrome phenotype is unclear, RCAN1 knockout in Drosophila 
melanogaster causes mental retardation and learning deficits.  In contrast, 
overexpression of RCAN1 causes increased sensitivity to oxidative stress and 
hyperphosphorylation of tau proteins, which results in the destabilization of 
filaments and tubules in Alzheimer’s disease. This suggests that its function 
possibly contributes to part of the cognitive decline that increases with age (Park 
et al., 2008).   
Also located in the DSCR is V-ets erythroblastosis virus E6 oncogene 
homolog 2, or Ets2, which is both a transcriptional activator and a repressor of 
cellular proliferation, differentiation, and tumorigenesis (Chatterjee, et al., 2013).  
Ets2 contributes to, but is not solely responsible for, the mandibular abnormalities 
of DS.  When overexpressed, Ets2 increases the rate of neuronal apoptosis and 
APP gene transactivation (Chatterjee et al., 2013).   
SIM2, or Single minded 2, located in the DSCR, belongs to a basic-helix-
loop-helix family of transcription factors. Important for normal neuronal 
development, this gene can translocate to the nucleus to transcriptionally 
regulate gene expression (Chatterjee et al., 2013).  SIM2 expression has been 
identified in fetal brain regions that contribute to Down syndrome pathology.  
SIM2 plays an important role in inhibition of carcinogen metabolism.  It is 
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consistently overexpressed in cancers of the prostate, colon, and pancreas, and 
it has additionally been suggested to have tumor suppressive utility in the breast.  
Consequently, SIM2 is often studied as tumor marker for several cancers and 
has the potential to be a drug target in the treatment of abnormal cell growths 
(Chatterjee et al., 2013). 
Down syndrome cell adhesion molecule (DSCAM) is a member of the 
immunoglobulin superfamily that highly expressed in the developing heart, and it 
thus is a likely candidate for producing the heart defect typical of Down syndrome 
(Yamakawa, et al., 1998).  Members of the immunoglobulin family in the brain 
are thought to be essential to neural development, cell migration, and synaptic 
plasticity (Yamakawa et al., 1998). Critical to brain development and present in 
brain areas with excessive synaptic activity, DSCAM also plays a role in 
dendritogenesis of neurons in the hippocampus (Alves-Sampaio et al.,2010).  
Increased levels of DSCAM have been reported in Down syndrome patients, as 
well in inhibition of dendritic branching.  However, its function in the adult brain 
has not yet been defined. 
Superoxide dismutase 1, or SOD1, a copper and zinc-binding enzyme that 
is encoded in the DSCR, has been most often studied in relation to metabolism.  
Superoxide dismutase converts oxygen free radicals to hydrogen peroxide.  This 
enzyme is critical because a high level of oxygen free radicals causes damage to 
cellular components and mitochondrial DNA, a process known as oxidative 
stress (Rueda et al.,  2012). It has been established that Down syndrome 
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individuals have more hydrogen peroxide production in the mitochondrion, which 
is also associated with oxidative stress. High levels of SOD1, when unmatched 
by a proportional increase of detoxifying enzymes, promote oxidative damage 
that contributes to neurodegeneration (Head et al., 2013).  Moreover, there is a 
50% increase of SOD1 in cells of Down syndrome patients compared to healthy 
patients, which will increase conversion of oxygen free radicals to hydrogen 
peroxide. Therefore, for people with DS, some cells are in constant danger of 
being damaged due to SOD1 up-regulation (Rueda et al., 2012). 
Amyloid precursor protein, or APP, is a protein whose proteolysis 
generates β amyloid.  APP is found in many organs and body systems, including 
the central nervous system.  The APP gene does not map to chromosome 21, 
but it promotes neurodegeneration and is associated with a number of neurologic 
diseases. β Amyloid accumulation within the neuron directly triggers a cascade of 
neurodegeneration.  Triplication of APP is known to cause early onset 
Alzheimer’s (Wilcock & Griffin, 2013).  APP is overexpressed by about 5 fold in 
DS, leading to a considerable overexpression of β amyloid protein. In fetal DS, 
increased levels of S100B are present. (Wilcock & Griffin, 2013).  S100B is an 
astrocyte-derived cytokine that is encoded by a gene located in the DSCR; it 
functions part of the inflammatory response.  It also contributes to healthy 
neuronal growth and maintenance, and protects growth after injury.  Excess 
S100B is associated with an increase in β amyloid.  The expression of APP and 
S100B are thought to be linked, suggesting that either a chromosome 21 gene 
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that directly leads to proliferation of both genes, or that there is a protein that 
induces the synthesis of both. DYRK1A, ETS2, RCAN1, SIM2, SOD1, S100B, 
DSCAM, and APP are each associated with an aspect of the Down syndrome 
phenotype, and are often the focus of Trisomy 21 studies. 
 
Mouse Models 
Mouse models of Down syndrome are fundamental to understanding the 
genetic aspects of the disease.  They allow for the investigation of many subjects 
in a short period of time, genetic manipulations based on areas of interest, and 
are relatively inexpensive.  However, not all of the neurological differences 
between mice and humans are known, which challenges the foundation on which 
evaluation of these mouse model outcomes is based. Cognitive function in 
humans is much more complex and interdependent than in mice. Moreover the 
orthologue of human chromosome 21 maps to multiple mouse chromosomes 
including Mmu, Mmu17, and Mmu10 (Rueda et al., 2012).  As a result, some 
models have an extra copy of the mouse region orthologous to human 
chromosome 21, while others have extra copies of specific genes from human 
chromosome 21 or their mouse equivalents (Antonarakis et al., 2004).  The 
structural and functional changes that are commonly targeted in mouse models 
are: reduction in cerebellar volume, enlargement of the lateral ventricle, defects 
in cell proliferation, motor dysfunction, poor balance, hyperactivity, and impaired 
performance of hippocampal dependent tasks (Rueda et al., 2012). 
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Intellectual Disability as the Focus 
Intellectual disability, formerly known as mental retardation, is a prominent 
feature of DS.  It consists of a constellation of symptoms including an impaired 
ability to learn new skills and complex ideas, inability to adapt to new conditions, 
and a limited capacity to manage daily tasks independently (Salvador-Carulla et 
al., 2011; Ropers, 2008).  For an official diagnosis of intellectual disability, a 
patient must have an IQ below 70 and significant limitations in ability to carry out 
everyday tasks. These features can be assessed by a standard IQ test and must 
begin before adulthood (Salvador-Carulla et al., 2011).  Identifying the root cause 
of intellectual disability associated with Down syndrome could have a major 
impact on preventing the impairments and lifelong dependence and care that 
come with the condition. 
In summary, Trisomy 21 is a complicated genetic syndrome that creates a 
host of physical, mental, and health related problems for sufferers. As the most 
common autosomal aneuploidy that produces live births, understanding how the 
genotype and associated phenotypes arise are useful for developing possible 
treatments for the disease in the future.  Given the range of phenotypic 
differences found in this condition, it is useful to develop mouse models that 
accurately reflect the chromosomal changes that take place in the human Down 
syndrome.  This study seeks to narrow down which specific gene or genes that 
underlie the intellectual disability in this disease.  These genes could give insight 
into the steps necessary to cause this type of dysfunction in the human brain. 
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This information could take the research community one step closer to defining 
the minimal gene products underlying the intellectual disability that is the 
hallmark of Down syndrome. 
 
Bioinformatics Approach 
Exploring Down syndrome using mouse models may not tell the whole story 
behind the gene products underlying the intellectual disability associated with 
DS.  Though these models are extremely useful, they may not be the most 
efficient way to observe relationships between genes or gene enrichment.  In 
order fill in that gap, a bioinformatics approach can be used to gain a unique 
perspective on the relationships between the genes on chromosome 21.  
Bioinformatics databases allow information from multiple origins to be compiled 
and compared rapidly so that novel predictions can be made.  These databases 
can be used to find information about each of the genes on chromosome 21.  It 
may be possible to narrow down which genes contribute to learning, memory, 
and cognition and make educated guesses about what ultimately causes 
intellectual disability. In combination with expression data, bioinformatics can 
help to bridge the gap between observable mouse model data, expression data 
and gene-gene interactions.  Combining these tools in research can be used to 
direct future experimental approaches.   
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SPECIFIC AIMS 
In order to determine possible ways to advance the current understanding of 
human Trisomy 21, this report will: 
Investigate the characteristics of the current mouse models of Trisomy 21  
• Determine the main similarities and differences between the Ts65Dn, 
Ts1Rhr, and Tc1 models  
o What genes are trisomic in each model? What tasks do mice 
perform normally and abnormally? How do these performances 
compare to the Down syndrome phenotype? 
Draw conclusions about how each model represents intellectual disability 
• How do mice perform in learning and memory tasks? (Which tasks do the 
mice perform adequately that should be impaired?)  
Propose the use of bioinformatics to investigate the relationships between the 
genes on chromosome 21  
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PUBLISHED STUDIES 
A great deal of Down syndrome research involves the use of mouse 
models in which the expression of a particular gene or gene set is triplicated in 
order to mimic the effects of human trisomy 21.   These models provide a means 
to determine the contribution of specific genes to the phenotypic features of DS.  
Several mouse models have been developed, as outlined in Table 1.   
Behavioral Tests 
Behavioral results are used to determine the presence or absence of 
dysfunction of specific brain regions.  Performance on learning and memory 
tasks is the most telling because it is also comparable to testing performed on 
humans with DS.   
The novel object recognition test is used to test memory (Das & Reeves, 
2011).  It assesses the instinctive tendency of mice to prefer exploring unfamiliar 
objects to common ones.  Initially, mice are given the chance to freely roam an 
area in order to become accustomed to the location in which the test will be 
performed.  Then two objects are introduced into the testing area for a brief 
period of time.  A day later, one of the objects is removed and a new object is 
introduced.  Normal mice are inclined to spend time exploring a novel object 
compared to a familiar one.  Mice with impaired memory, on the other hand, do 
not prefer a novel object to a familiar one.  The time spent exploring both novel 
and familiar objects is recorded.  Mice being used to study Down syndrome 
should have impaired performance on this task (Das & Reeves, 2011).   
 24 
The Morris water maze is often used to assess learning and memory.  The 
task consists of a pool with a platform submerged in water that the mouse must 
try to find.  Once the mouse has become accustomed to the conditions of the 
arena, the water is made cloudy such that the mouse must find the hidden 
platform by using visuospatial cues (Das & Reeves, 2011).  Evaluation of a 
mouse’s performance is based the amount of time it takes to find the platform. 
 
Mouse models of Trisomy 21 
The Ts1Rhr and Ts65Dn models of Down syndrome are both based on 
trisomies of mouse orthologs of syntenic regions of mouse genes. Ts65Dn mice 
are trisomic for 104 orthologs of chr21 genes (Davisson et al., 1993). An initial 
approach was to make a model that was trisomic for the entire Mmu16, and thus 
the Ts1Rhr model was created (Olson et al., 2004).  
The original purpose of the Ts1Rhr model was to evaluate the contribution 
of genes in the Down syndrome critical region to the Down syndrome facial 
abnormalities (Olson et al., 2004). The Ts1Rhr model is trisomic for the 33 genes 
in the Down syndrome critical region, the region that was originally thought to 
contain loci required for development of Down syndrome (Korenberg et al., 
1990). The Ts1Rhr model is extremely useful for observing the craniofacial 
abnormalities associated with Down’s because it gave evidence that trisomy of 
this region alone was not sufficient to produce facial abnormalities (Olson et al., 
2004). They were also initially used to study brain irregularities, since they exhibit 
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a reduced cerebellar size (Olson et al., 2004). Moreover, traits of these mice are 
inconsistent with the resultant performance on tasks often varying between 
studies (Aldridge et al., 2007; Yu et al., 2011; Olson et al., 2004). This diminishes 
the etiologic similarities between HSA21 and the mouse correlate, causing this 
model to fall out of favor (Aldridge et al., 2007; Yu, et al., 2011; Olson, et al., 
2004). 
Next, a mouse model was developed that contained partial aneuploidies of 
genes orthologous to those found on chr21. The Ts65Dn model was created 
through the production of embryonic stem cells carrying orthologs of the Down 
syndrome critical region genes (Olson et al., 2004).  It contains partial trisomy of 
Mmu16 and partial trisomy of Mmu17 and is trisomic for 94 genes (Davisson et 
al., 1993). Phenotypically, this model adequately presents many Down syndrome 
features including craniofacial skeletal deformities, reduced cerebellar volume 
and deficient hippocampal function (Davisson et al., 1993).  The Ts65Dn model 
also matches the decreased hippocampal acetylcholine release pattern that is 
found in human adults with Down Syndrome and dementia, the same 
insufficiency that is linked to memory loss with aging (Holtzman et al., 1996). 
Moreover, this model shows an increase in amyloid precursor protein activity, 
which decreases differentiation and maintenance of neurons (Holtzman et al., 
1996). Ts65Dn mice are not impaired in muscular strength, motor abilities, 
sensation, and do not mimic the hypotonia that is found in T21 (Baxter et al., 
2000; Escorihuela et al., 1995).  Though this model is helpful, Mmu17 is syntenic 
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for multiple human chromosomal regions, which causes the model to contain 
aneuploidy of areas that are not triplicated in Down syndrome (Duchon et al., 
2011).  The Ts65Dn mouse model of human Down syndrome has been 
repeatedly studied and is still frequently used. 
The Ts1Rhr model is trisomic for 33 genes orthologous to those found in 
the DSCR, all of which are found on a portion of Mmu16 (Patterson, 2009).  It 
contains three copies of DYRK1A, 3 copies of Ets2, and 2 copies of RCAN1.  It 
produces a mouse with craniofacial abnormalities, a mandible that is 
morphologically different than non Down syndrome individuals, reduced brain 
volume during younger years but not later in life, reduced cerebellar volume, and 
impaired hippocampal long term potentiation (Dierssen et al.,  2009).  However, 
the impairment in learning and memory tasks from the Ts65Dn model are not 
present in the Ts1Rhr model.  Moreover, the craniofacial abnormalities are less 
pronounced in this model than in the Ts65Dn.  In contrast to Ts65Dn, body 
weight measures show that Ts1Rhr mice have larger overall body size relative to 
euploid (Aldridge et al., 2007).  Of the three models examined, the Ts1Rhr model 
did not show evidence of learning and memory deficiencies, a decrease in 
attention, a craniofacial defect, or hyperactivity, which are all present in the 
human condition. 
The Ts1Rhr and Ts65Dn segmental mouse models were prominently 
used to study Down syndrome until the Tc1 model was created in 2005 
(O'Doherty et al., 2005). The Tc1 mouse model is one of the most recent and 
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precise models of the condition to date. It was created by obtaining human 
chromosome 21 from a donor cell line and fusing the donor cells with mouse 
embryonic stem cells.  The subsequent cell that contained the largest fragment of 
chromosome HSA21 was injected into the mouse embryos early in development.  
Once the embryos were re-inserted into the mother mouse, the offspring were 
crossed with euploid mice to produce Tc1 mice (O'Doherty et al., 2005).  Thus 
this trans-species aneuploid mouse model carries an extra copy of human 
chromosome 21, and thus only triplicates genes that are triplicated in human 
Down syndrome (O'Doherty et al., 2005).  For this reason, this model is likely to 
be an extremely accurate representation of the gene dosage effects that exists in 
trisomic individuals (O'Doherty et al., 2005).  For example, intellectual disability, 
the classic feature of Down syndrome, is reflected in the deficits in behavioral 
tests of learning and memory (Ahmed et al., 2013). Moreover, Tc1 mice show 
other traits of human Down syndrome, such as abnormal heart development, 
mandibular size, and synaptic plasticity (Galante et al., 2009).  A notable 
drawback of the Tc1 mouse model is that the mice show a high degree of 
mosaicism, such that not every cell is trisomic for chromosome 21 (Patterson, 
2009; Galante et al., 2009).  This can become problematic and time-consuming 
when a researcher needs to determine if the individual cells being used in an 
experiment are trisomic, especially if their experiment has already been 
completed.  Therefore a larger sample size may be necessary to prove statistical 
significance. 
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As Table 1 indicates, there are important similarities between the main 
models, including decreased cerebellar size, heart defect, and triplication of 
genes DYRK1A, ETS2, SIM2, SOD1, S100B, and DSCAM.  This is because of 
the loci containing all of these genes are triplicated in each of these models.  The 
Ts1Rhr model has the fewest abnormalities in common with trisomy of HSA21; it 
does not have three copies of RCAN1 or APP, impaired performance learning 
and memory, attention, activity, or a craniofacial defect.  Also, the typical 
performance of Ts1Rhr mice on balance and motor coordination tasks was not 
found.  The Ts65Dn mice have traits more similar to human T21; the only studied 
trait they did not have is a decreased cerebral size.  Finally, although Tc1 mouse 
information was not found regarding body weight and cerebral size, every other 
characteristic investigated exhibited the same qualities as human trisomy 21. 
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Table 1. Summary of Ts65Dn, Ts1Rhr, and Tc1 Models 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From: (Rueda et al, 2012; Aldridge et al., 2007; O'Doherty, et al., 2005; 
Galante, et al., 2009) 
 
  
 T21 Tc1 Ts65Dn Model Ts1Rhr 
Model 
Gene Trisomy of 
HSA21 
Trisomy of HSA1; 
transchromosomic 
Trisomy of 
Mmu16, Part of 
17 
Trisomy of 
Mmu16 
DYRK1A 3 copies 3 copies 3 copies 3 copies 
ETS2 3 copies 3 copies 3 copies 3 copies 
RCAN1 3 copies 3 copies 3 copies 2 copies 
SIM2 3 copies 3 copies 3 copies 3 copies 
SOD1 3 copies 3 copies 3 copies 3 copies 
S100B 3 copies 3 copies 3 copies 3 copies 
DSCAM 3 copies 3 copies 3 copies 3 copies 
APP 3 copies 3 copies 3 copies 2 copies 
     
Body Weight Increased - - - Decreased Increased 
Cerebral Size Decreased - - - No change Reduced at 
4 months 
Cerebellar 
Size 
Decreased Decreased Decreased Decreased 
     
Balance Poor Poor Poor  - - - 
Motor 
Coordination 
Poor Poor Poor  - - - 
Learning & 
Memory  
Impaired Impaired Impaired 
Performance 
Normal 
Attention Deficient Deficient Deficient Normal 
Activity 
Level 
Hyperactive Hyperactive Hyperactive Normal 
     
Heart Defect Present Present Present Present 
Craniofacial 
Defect 
Present Present Present Absent 
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Exploring relationships between the genes on chromosome 21 
Since the phenotypes of Trisomy 21 are presumed to be the result of increased 
chromosome 21 expression, Down syndrome can be explored by using gene 
expression data to determine how the gene dosage effect influences 
overexpression of specific genes on chromosome.  Gene transcription studies 
have contributed to our current understanding of the molecular consequences of 
gene dosage through quantitative analysis of trisomic tissues compared to 
euploid in order to identify what transcriptional modifications are occurring.  They 
also facilitate identification of genes that are specifically expressed in the brain.  
These studies have provided evidence for the gene dosage effect and support 
the notion that the change in expression of chromosome 21 genes and their 
proteins results from the presence of a triplication (Mao et al., 2003; Fitzpatrick et 
al., 2002).  One study of T21 samples showed an up-regulation in gene 
expression that is specific to chromosome 21, further supporting the gene 
dosage hypothesis (Mao et al., 2003).  In this study, astrocyte cell lines and 
frozen fetal brain samples were analyzed.  The astrocyte cell lines, which 
represented a uniform sample, and the brain samples, which included several 
cell types, were extracted from T21 fetuses and their expression levels were 
compared to euploid.  In both cases, the chromosome 21 genes were 
significantly up regulated compared to euploid (Mao et al., 2003). 
 Moreover, studies that compare aneuploid human tissues or cell lineages 
to euploid have allowed for the observation of transcriptional changes (Rachidia 
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& Lopesa, 2007).  For example, Mao et al. used microarrays to observe gene 
expression in the developing brain.  Through the use of frozen fetal Down 
syndrome and normal brain samples, they observed up-regulation of expression 
of genes on chromosome 21, including Down syndrome associated genes APP, 
SOD1, S100B (Mao et al., 2003). 
In the search for the genetic cause of intellectual disability, expression 
data could be used to narrow down the possible candidates.  Once the candidate 
genes related to learning, memory, and cognitive function are determined 
expression data can be used to investigate how these genes a regulated in 
trisomic individuals when compared to normal individuals. 
 
Using bioinformatics to look at chromosome 21   
 Bioinformatics involves the use of computer-based algorithms to compile 
and analyze large amounts of scientific data.  These tools are invaluable in the 
field of genomics, where large gene lists and sequencing data can be organized 
and compared across multiple organisms. In the field of genetic diseases, these 
tools can be used to study individual genes or gene sets and their annotations in 
a bioinformatics resource. The figure below outlines the proposed utility of the 
UCSC Genome Bioinformatics Site and the Database for Annotation, 
Visualization and Integrated Discovery to study trisomy 21 associated intellectual 
disability. 
 32 
Figure 6. Bioinformatics Proposal 
 
The UCSC Genome Bioinformatics Site (genome.ucsc.edu) is a free online 
reference tool used to search, display and explore genomes. The Genome 
Browser, a function within the UCSC database, is used to identify which genes 
are found at a given location on the chromosome.  The genomic displays are 
complete with annotations from various researchers and information about the 
UCSC Genome 
Browser 
• Obtain a list of 
chromosome 21 
genes 
Submit genes to 
DAVID for analysis 
DAVID will recognie 
unique genes and 
make them available 
for further analysis 
Functional Annotation 
Clustering--based on 
"biological meaning" 
given by database 
annotations 
BIOINFORMATICS PROPOSAL 
Gene Functional 
Classification - -based 
on "function" 
determined by 
database annotations 
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genes.  These annotations are useful because they allow the user to view and 
upload experimental results related to a specific gene or gene set.  The Browser 
is also used to search for genes known to be associated with disease.  In the 
case of Down syndrome, a tool such as this could be used to determine what 
disease related genes are on the chromosome.  It can also be used to determine 
if any genes related to intellectual disability are on the chromosome, and what 
experimental data exists on these genes. 
 The Database for Annotation, Visualization and Integrated Discovery, or 
DAVID, is bioinformatics software database that is used to discover functional 
relationships between genes in a gene set.  This resource also compiles 
information from a variety of bioinformatics sources (Huang et al., 2000).  Like 
the UCSC Genome Bioinformatics Site, DAVID also compiles information from 
many different sources and allows the user to look for experimental data related 
to their gene list. The Functional Annotation Clustering and Gene Functional 
Annotation algorithms in the DAVID database are used to identify potentially 
“enriched” functionally related genes in a gene set, cluster genes that have 
annotation terms in common, and pinpoint enriched themes or features across a 
gene cluster in order to gain a more in depth understanding of what relationships 
between genes may exist (Huang et al., 2000).  
A gene list extracted from the UCSC genome browser can be put into 
DAVID for analysis.  When a gene list is submitted, the software first recognizes 
each unique gene such that genes that appear more than once or alternatively 
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spliced forms of the same gene will only be only counted once. The Functional 
Annotation Clustering device in DAVID creates gene clusters based on 
similarities in “biological meaning” within a gene list. A “biological meaning” is 
defined by the features of the genes and the processes in which they play a role 
(Huang et al., 2000); in the database, it is given by the annotations of a gene in 
the database. In other words, these clusters represent groups of genes with 
similar annotations in the database. The algorithm sorts genes into clusters 
based on similarity in biological meaning, and then gives each member of that 
group an enrichment score.  The enrichment scores for each cluster are based 
on the average score of each term in the cluster. An “enriched” score for a cluster 
signifies that the members in a given group are more significant (enriched) to a 
given gene list.  This can mean that a cluster has members that are more 
functionally similar to each other, or that a cluster has many annotation terms in 
common.  In terms of enrichment scoring, a score of 1.3 is a significance value of 
0.05 on the non-logarithmic scale. Therefore the software dictates that any score 
below 1.3 represents a grouping or clustering that is likely due to chance and is 
not “enriched” (Huang et al., 2000).   
For the study of T21, the functional annotation tool could be used to 
examine the clusters that were derived from the database.  The clusters could 
then be examined for the presence of annotation terms known to be associated 
with intellectual disability.  It would also be prudent to look for terms related to 
brain development, learning, and memory and see how the clustered genes work 
 35 
together, how they are regulated, and how they are affected during development. 
The database can also generate an output from the Gene Functional 
Classification tool, which is an algorithm that classifies genes based on functional 
relationships between genes and creates “groups” of genes based on which 
annotation terms are common between these functionally related genes (Huang 
et al., 2000).  Genes that are put in the same group are thought to work together 
or have a similar overall function. For Gene Functional Classification, significance 
scores tell how functionally related a gene is to the rest of the group and 
therefore which gene families are enriched (Huang et al., 2000). 
Bioinformatics can be used in several different ways.   In Down syndrome 
research, these tools can be important assets for narrowing the genetic cause of 
intellectual disability.  The UCSC Bioinformatics tool can be used to obtain a list 
of genes on the chromosome. DAVID can be used to look more closely at the 
individual genes, determine their functions, investigate how they interact with 
each other, and define what contributions they make to learning and memory. 
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CONCLUSION AND FUTURE DIRECTIONS 
Implications of the current mouse models 
For a mouse model to appropriately reflect the intellectual disability 
present in Down syndrome, performance on learning and memory tasks must be 
impaired. The Tc1 and Ts65Dn mouse models of trisomy 21 have deficits in 
learning and memory tasks, which makes them valuable for the study of 
intellectual disability. Since the Tc1 mouse model contains the same human 
chromosome triplication as T21, this model should have all of the same 
phenotypic traits, developmental abnormalities, and gene dosage effect that are 
seen in human Down syndrome.  The Ts65Dn model is also extremely useful for 
T21 studies because, as shown in Table 1, it accurately represents each 
phenotype examined except for cerebral size.  Both of these models have 
notable worth (Antonarakis, Lyle, Dermitzakis, Reymond, & Deutsch, 
2004)across multiple Down syndrome traits. 
The Ts1Rhr model does not display the features that typically indicate 
intellectual disability in mice and thus is not the best model to use to find the 
genetic cause of that trait.   Since the major difference between the Ts1Rhr 
model and the Ts65Dn model is the presence of an extra the portion of Mmu17 in 
the Ts65Dn model, it is possible that the Mmu17 portion of the mouse 
chromosome contributes to the manifestation of this trait.  However, since the 
Ts1Rhr model accurately reflects the increased body weight, heart defect, and 
decreased cerebellar size seen in human trisomy, it could be useful for the study 
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of body mass index, cardiovascular development, and cerebellar functioning 
studies in Down syndrome patients.   
Furthermore, human chromosome 21 is represented by more than one 
chromosome in mice, which limits the utility of Ts1Rhr and Ts65Dn models in the 
general study of Down syndrome because they may contain euploid genes that 
are aneuploid in T21 or aneuploid genes that are not a part of chromosome 21 
and thus should be euploid.  Since the Tc1 model is transchromic, it is expected 
that this model will most accurately reflect the entire pattern of T21 dysfunctions, 
including intellectual disability. 
 
Finding relationships between genes 
Gene ontology is a bioinformatics concept that involves systematizing the 
representation of genes and their products across different databases and 
species. DAVID, for example, uses data from a number of different bioinformatics 
sources and compiles them such that information it gives on a specific gene list is 
a summary of the information available from a combination of different original 
sources. The UCSC genome browser and DAVID can be both used as a unique 
way to interpret the genes on chromosome 21 from the perspective of genetic 
researchers.   
Intellectual disability is the classic trait that results from trisomy 21.  
Symptoms are a direct consequence of the gene dosage effect associated with 
the genetic disorder, either through an increase of expression in genes that are 
dosage sensitive or regulatory gene sequences on the chromosome that play 
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some undetermined role in brain function.  As the most common genetic disease 
in the United States, the impact of Down syndrome is unquestionable.  Down 
syndrome is not only associated with a slew of physical and mental problems 
later in life, but also a reduced life span and reduced ability to care for oneself.  
Intellectual disability manifests as decreased ability to communicate with others, 
below average intelligence, and a lack of skills necessary for day-to-day tasks.  
Through the use of effective mouse models and bioinformatics, researchers can 
work toward lessening the disadvantages Down syndrome sufferers face.  Once 
more specific candidate genes for the cause of the intellectual disability are 
identified, new treatments may be developed which lessen the disease burden 
on sufferers of Down syndrome.    
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